Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials (vol 385, pg 2606, 2015)

Sax P. E.; Wohl D.; Yin M. T.

首页> 外文期刊>The Lancet >Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials (vol 385, pg 2606, 2015)

【24h】

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials (vol 385, pg 2606, 2015)

机译：替诺福韦alafenamide与替诺福韦富马酸替索洛韦联合elvitegravir，cobicistat和恩曲他滨联合配制，用于HIV-1感染的初始治疗：两项随机，双盲，3期，非劣效性试验（第385卷，第2606页，2015年）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Lancet》 |2016年第10030期|共1页
作者
Sax P. E.; Wohl D.; Yin M. T.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
专利

1. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials (vol 385, pg 2606, 2015) [J] . Sax P. E., Wohl D., Yin M. T. The Lancet . 2016,第10030期

机译：替诺福韦alafenamide与替诺福韦富马酸替索洛韦联合elvitegravir，cobicistat和恩曲他滨联合配制，用于HIV-1感染的初始治疗：两项随机，双盲，3期，非劣效性试验（第385卷，第2606页，2015年）
2. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials [J] . Sax Paul E., Wohl David, Yin Michael T., The Lancet . 2015,第9987期

机译：Tenofovir alafenamide与替诺福韦解毒富马酸盐，用elvitegravir，cocicistat和emtrickabine，用于初始治疗HIV-1感染：两个随机，双盲，第3期，非劣级试验
3. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials [J] . Sax Paul E., Wohl David, Yin Michael T., The Lancet . 2015,第9987期

机译：替诺福韦alafenamide与替诺福韦二富马酸富马酸联合与依维福韦，cobicistat和恩曲他滨共同配制，用于HIV-1感染的初始治疗：两项随机，双盲，3期非劣效性试验
4. A Trial of a Single-tablet Regimen of Elvitegravir Cobicistat Emtricitabine and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal West Africa [O] . Selly Ba, Dana N Raugi, Robert A Smith, -1

机译：ElvitegravirCobicistatEmtricitabine和Tenofovir Disoproxil Fumarate的单片治疗方案在资源有限的环境中用于人类免疫缺陷病毒2型感染的初始治疗的试验：西非塞内加尔48周结果
5. A randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: Week 96 results [O] . Wohl David D., Cheret Antoine A., Brunetta Jason J., 2016

机译：替诺福韦阿拉芬酰胺和替诺福韦富马酸替诺福韦的随机，双盲比较，每种药物与elvitegravir，cobicistat和恩曲他滨共同配制：最初的HIV-1治疗：第96周结果

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials (vol 385, pg 2606, 2015)

著录项

相似文献

相关主题

期刊订阅